View Older Stories View More Recent Stories
-
Stifel Reiterates Buy Rating on Becton Dickinson (BDX)
-
Stifel Reiterates Buy Rating on Becton Dickinson (BDX)
-
Becton Dickinson (BDX) PT Lowered to $241 at Barclays
-
Piper Sandler Highlights 'Best Value Stocks' in Medical Technology
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Citi Downgrades Becton Dickinson (BDX) to Neutral
-
Wall Street analysts downgrade Becton Dickinson as 'confidence eroded'
-
Becton Dickinson (BDX) PT Lowered to $255 at Jefferies
-
Raymond James Downgrades Becton Dickinson (BDX) to Market Perform, 'Lower Growth Warrants Lower Rating'
-
Piper Sandler Downgrades Becton Dickinson (BDX) to Neutral
-
Goldman Sachs Downgrades Becton Dickinson (BDX) to Neutral
-
Becton Dickinson (BDX) PT Lowered to $224 at Stifel
-
Becton Dickinson (BDX) call put ratio 1 call to 1.2 puts on active option volume of 7800 contracts as share price down 15.7%
-
BofA Securities Downgrades Becton Dickinson (BDX) to Neutral
-
Becton Dickinson (BDX) Tops Q2 EPS by 7c; offers guidance
-
Becton Dickinson (BDX) Declares $1.04 Quarterly Dividend; 2% Yield
-
Becton Dickinson (BDX) PT Lowered to $260 at Piper Sandler
-
Becton Dickinson (BDX) Launches Bioabsorbable Mesh Designed for Umbilical Hernia Repair
-
Becton Dickinson (BDX) Appoints Gregory J. Hayes to its Board
-
Becton Dickinson (BDX) Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE Scaffold in Breast Implant Revision Surgery
-
BofA Comments on Trump and Mexico Tariff Delay Impact to Medical Technology Names
-
Increasing unusual put option volume: BDX DBX NXE IVZ NXE HLF GXO BMBL
-
Becton Dickinson (BDX) Tops Q1 EPS by 44c (from yesterday)
-
After-hours movers: Ford Motor, Qualcomm, Align Technology and more
-
Becton Dickinson (BDX) to Separate Biosciences and Diagnostic Solutions Business
-
Becton Dickinson (BDX) Said To Mull Life Sciences Segment Separation - Bloomberg
-
Becton Dickinson (BDX) Announces Share Buyback, Declares Dividends
-
Becton Dickinson (BDX) PT Raised to $280 at Piper Sandler Amid Potential Life Sciences Spin-Off'
-
Becton Dickinson (BDX) Boosts U.S. Manufacturing of Critical Medical Devices
-
Becton Dickinson (BDX) names Pamela Spikner CAO and controller
-
Increasing unusual call option volume: QUBT KULR NGD AISP MVST PRGO CRC RGTI QBTS BDX
-
Becton Dickinson (BDX) and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations
-
SEC: Becton Dickinson (BDX) to Pay $175M for misleading investors
-
KeyBanc on ICU Medical (ICUI): 'Survey suggests potential market share gains for ICUI'
-
Barclays highlights most and least sensitive MedTech stocks to changes in surgical volumes
-
Becton Dickinson (BDX): First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
-
Becton Dickinson (BDX) Tops Q4 EPS by 4c ; Offers Guidance
-
Becton Dickinson (BDX) Tops Q4 EPS by 4c; offers guidance
-
Becton Dickinson (BDX) Raises Quarterly Dividend 9.5% to $1.04; 1.7% Yield
-
Becton Dickinson (BDX) Launches Enhanced Intraosseous System
-
Becton Dickinson (BDX) Announces New Robotics Solution to Automate, Standardize Single-Cell Research
-
Becton Dickinson (BDX) Reaches Agreement to Resolve Vast Majority of Hernia Litigation
-
Citi Upgrades Becton Dickinson (BDX) to Buy
-
Becton Dickinson (BDX) Completes Acquisition of Critical Care from Edwards Lifesciences
-
Becton Dickinson (BDX) Appoints Michael Feld as President of Life Sciences Segment
-
Becton Dickinson (BDX) PT Lowered to $305 at Jefferies
-
Becton Dickinson (BDX) Tops Q3 EPS by 19c, provides guidance
-
Becton Dickinson (BDX) and Quest Diagnostics (DGX) Collaborate to Develop Companion Diagnostics for Cancer, Other Diseases
-
Becton Dickinson (BDX) Declares $0.95 Quarterly Dividend; 1.6% Yield
-
Becton Dickinson (BDX) Surpasses Scope 1 and 2 Reduction Milestones for FY 2023
